Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Intranasal Corticosteroids Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The intranasal corticosteroids market size has experienced robust expansion in recent years. Projections indicate an increase from $6.78 billion in 2025 to $7.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this historical growth include limited knowledge of intranasal corticosteroids, a dependence on hospital pharmacies for drug dissemination, a rising occurrence of nasal allergies, a preference for traditional treatment approaches, and restricted availability of online pharmacies.
The intranasal corticosteroids market is projected to experience substantial expansion in the coming years, with its size reaching $9.74 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is attributed to heightened healthcare awareness, the proliferation of retail and online pharmacies, an increasing incidence of chronic rhinitis and nasal polyps, the adoption of combination therapies, and the development of patient-friendly spray devices. Key trends for the forecast period include a rising prevalence of allergic rhinitis and nasal disorders, an increase in the adoption of prescription intranasal corticosteroids, a surge in over-the-counter intranasal corticosteroid use, the expansion of hospital and homecare distribution channels, and an emphasis on patient-centric treatment and ease of administration.
Get A Free Sample Report With In-Depth Market Insights:
Intranasal Corticosteroids Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The rising occurrence of allergic rhinitis is anticipated to stimulate future expansion within the intranasal corticosteroids market. This condition constitutes an allergic response leading to inflammation within the nasal passages, frequently initiated by airborne irritants like pollen, dust mites, mold, or pet dander. Its growing prevalence largely stems from escalating environmental pollution, which exposes people to airborne allergens and irritants, thus prompting allergic reactions in their nasal passages. Intranasal corticosteroids assist in managing allergic rhinitis through the reduction of nasal passage inflammation, thereby alleviating symptoms including sneezing, congestion, and a runny nose. For example, data from October 2023, provided by the National Library of Medicine, a US-based biomedical library, indicates that allergic rhinitis impacts more than 400 million individuals globally, with estimated prevalence rates of 10% to 30% in adults and exceeding 40% in children. Consequently, the increasing prevalence of allergic rhinitis acts as a significant driver for the intranasal corticosteroid market.
Intranasal Corticosteroids Market Segment Analysis Spotlighting Growth Areas
The intranasal corticosteroids market covered in this report is segmented –
1) By Drug Types: Prescribed Drugs, Over-The-Counter Drugs
2) By Application: Allergic Rhinitis, Nasal Polyps, Sinusitis, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
4) By End User: Hospitals, Clinics, Homecare, Healthcare Providers
Subsegments:
1) By Prescribed Drugs: Fluticasone Propionate, Mometasone Furoate, Budesonide, Beclomethasone Dipropionate, Ciclesonide
2) By Over-The-Counter Drugs: Triamcinolone Acetonide, Fluticasone Furoate, Budesonide Over-The-Counter Drugs
Intranasal Corticosteroids Market Innovation Trends Shaping Future Development
Leading companies within the intranasal corticosteroids market are prioritizing the development of innovative formulations, such as nasal sprays, to optimize targeted drug delivery and improve patient adherence. These liquid medications are administered directly into the nose via a spray nozzle to address conditions including allergies, congestion, or inflammation. They facilitate rapid drug absorption through the nasal mucosa, offering quick relief with minimal systemic effects. For instance, in March 2024, OptiNose Inc., a US-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for XHANCE, which is the first and only treatment specifically indicated for adults suffering from chronic rhinosinusitis (CRS) without nasal polyps. This nasal spray incorporates a unique exhalation delivery system, allowing the medication to reach deep into the nasal cavity, thereby effectively treating CRS in adults, with or without nasal polyps. Each spray dispenses 93 mcg of fluticasone propionate, and the device operates by requiring the user to blow into a mouthpiece while simultaneously releasing the spray into the nostril, ensuring precise delivery and enhanced symptom relief.
Intranasal Corticosteroids Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the intranasal corticosteroids market are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Haleon plc, Intas Pharmaceuticals Limited, Organon Pharma (UK) Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Limited, Cipla Ltd., Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, OptiNose US Inc., Taro Pharmaceutical Industries Ltd., Maya Biotech Private Limited, AdvaCare Pharma USA, Lupin Ltd., Xenone Healthcare Private Limited.
View The Full Intranasal Corticosteroids Market Report:
Intranasal Corticosteroids Market Geographic Spread And Regional Opportunities
North America was the largest region in the intranasal corticosteroids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intranasal corticosteroids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model